# Jiacong Guo

> Jiacong Guo is a seed investor at BioTrack Capital backing Biotechnology and Pharmaceutical. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital)
- Location: Shanghai, China
- Total investments: 3
- Last investment: Jan 2024
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jiacong-guo-phd-9a3b7849/?originalSubdomain=cn

Jiacong Guo is a seed investor at BioTrack Capital in Shanghai focused on Biotechnology and Pharmaceutical. Jiacong Guo

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Pharmaceutical | 2 | 67% |
| Oncology | 1 | 33% |
| Biopharma | 1 | 33% |
| Health Care | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Angel | 1 | 33% |
| Series A | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| OnCusp Therapeutics | OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments.It is always working to improve the largest value inflection point in the drug development value chain, believing that speeding oncology medication innovation is the most effective method to provide help and hope to cancerpatients around the world.It is founded by Bing Yuan, Eric Slosberg, and Andy Fu. | $100M | Series A | Jan 04, 2024 |  |
| Brise Pharma | Brise Pharma operates in the scientific research and technical service industry. | $23.3M | Angel | Oct 01, 2021 |  |
| OnCusp Therapeutics | OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments.It is always working to improve the largest value inflection point in the drug development value chain, believing that speeding oncology medication innovation is the most effective method to provide help and hope to cancerpatients around the world.It is founded by Bing Yuan, Eric Slosberg, and Andy Fu. | $25M | Seed | Apr 01, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together
- [AIHC Capital](https://shizune.co/investors/profile/aihc-capital) — VC Fund, 1 deal together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 1 deal together
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund, 1 deal together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 1 deal together
- [CJNV BioVentures](https://shizune.co/investors/profile/cjnv-bioventures) — VC Fund, 1 deal together

## About BioTrack Capital

VC Fund · Shanghai, China

BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.

4 contacts available at BioTrack Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Feng Tao | Co-Founder & Partner | https://shizune.co/investors/profile/feng-tao-481b |
| Jiacong Guo | Executive Director | https://shizune.co/investors/profile/jiacong-guo |
| Kevin (Penghui) Chen | Founder & Partner | https://shizune.co/investors/profile/kevin-penghui-chen |
| Zhang Ye | Project Manager | https://shizune.co/investors/profile/zhang-ye-1d05 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Jiacong Guo invest in?

Jiacong Guo invests primarily in Biotechnology, Pharmaceutical and Oncology startups, most often at Seed and Angel stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jiacong Guo last invest?

The most recent investment recorded for Jiacong Guo closed in Jan 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co